this is what Antibe's doing right now.excerpt from past article.they laid out the plan following successful phase 2
Over the summer Antibe revealed that it is in discussions with global partners in order to monetize its drug pipeline for the large pharmaceutical markets.
Given the strength of existing clinical results and upcoming results from its Phase 2B trials, CEO Dan Legault said the company is “well-positioned” to deliver high-value partnerships.
The company's Phase 2B efficacy study has a total of 360 patients across 35 clinical sites, in "one of the largest clinical studies ever undertaken in Canada," noted the firm. The company says a successful trial will validate the best-in-class status of the drug in a US$11 billion drug category and could set the stage for global partnering activity.
Assuming the results are positive, Antibe expects to be in a position to execute a series of regional and global licensing deals.
https://ca.proactiveinvestors.com/companies/news/905097/antibe-therapeutics-is-ready-for-a-big-push-as-it-progresses-pain-management-drug-through-clinical-trials-905097.html